Ocular Therapeutix Unveils Positive Results

Ocular Therapeutix said Wednesday it had positive results of a patient experience study of Dextenza (dexamethasone insert) for intracanalicular use. The study, published in Patient Preference and Adherence, evaluated the overall patient experience and perceived value of Dextenza following cataract surgery, the company said in a press release.

Inserted non-invasively through the punctum, Dextenza resides within the canaliculus and delivers dexamethasone to the ocular surface for approximately 30 days. Following the completion of treatment, Dextenza resorbs and exits the nasolacrimal system without need for removal, the company said.

The goal of Dextenza is to reduce the patient burden of administration of topical eyedrops following ophthalmic surgery by enabling the physician to control the entire course of steroid therapy with a single administration, the company said.

By Jon Flanagan